Elicio Therapeutics is re-engineering the body’s immune response to defeat cancer with potent lymph node targeted immunotherapies. Elicio’s Amphiphile platform combines expertise in materials science, immunology and immuno-oncology to develop novel immunotherapies, including cell therapy activators, immunomodulators, adjuvants and vaccines for an array of aggressive cancers.
Lymph nodes: where the immune response is orchestrated
Elicio has demonstrated preclinically that Amphiphiles target and concentrate an array of different immunotherapies in the lymph nodes, resulting in unprecedented tumor-specific immune responses and durable cures in multiple aggressive tumor models. Elicio’s lead Amphiphile program for KRAS-driven cancers will enter initial patient studies in 2020.
Elicio will begin multiple Phase 1/2 studies for ELI-002 in 2020. This program consists of an Amphiphile vaccine that has the potential to elicit powerful immune responses against KRAS, a mutation found in 90% of pancreatic cancers, and 40% of colorectal cancers.
September 17, 2020 ||
Elicio Therapeutics and Moffitt Collaborate to Study AMP-CD19 in Combination with CD19 CAR T cells
Elicio Therapeutics, a next generation immuno-oncology company, today announced that it has established a collaboration with the Moffitt Cancer Center to characterize combination therapies pairing Elicio’s CD19 Amphiphile and a universal FITC Amphiphile with CD19 CAR T cells. » Read more
September 3, 2020 ||
Next-gen Covid-19 vaccines: Elicio and its lymph node targeting approach
PHARMACEUTICAL TECHNOLOGY One next-generation Covid-19 vaccine that is about to enter clinical studies is Elicio’s ELI-005. This lymph node-targeting vaccine is composed of an adjuvant developed using the company’s Amphiphile technology and the SARS-CoV-2 virus’s spike protein RBD. Elicio head of research and development Christopher Haqq explains the differentiated mechanism of the action of this […] » Read more
Orchestrating the immune system for precision immunity — Download this articleto see how Elicio’s lymph node-targeting Amphiphile technology delivers potent T cell activation and boosts the effects of engineered cell therapies.